Scancell Holdings Plc ImmunoBody® Patent Approved for Grant in Japan

Scancell Holdings Plc, the developer of therapeutic cancer vaccines, is pleased to announce that a patent for its protein ImmunoBody® vaccine technology has been approved for grant in Japan. The patent has already been approved in the US, Europe and Australia.

Dr. Richard Goodfellow, Joint Chief Executive of Scancell, commented: “This is a further important step in the development and commercialisation of the ImmunoBody® platform and provides further evidence to support the novelty of Scancell’s  ImmunoBody®  technology in another key pharmaceutical market.  Scancell will continue building its growing portfolio of intellectual property in parallel with driving the clinical trial programme on SCIB1 forward during 2013.”